In the latest issue of Technology Networks, Michael Armstrong, MD, PhD, and Patrick Hurban, PhD, examine how ASCO 2026 highlights the growing convergence of biology, diagnostics and clinical strategy, enabling more precise oncology development and positioning innovators for greater clinical and commercial success.